Centanafadine SR 400 mg Shows 52-Week Tolerability in Adult ADHD
This open-label extension supplies the longest safety dataset yet for centanafadine, a norepinephrine/dopamine/serotonin triple reuptake inhibitor, and informs pharmacists about its likely tolerability, abuse-potential profile, and monitoring needs in adult attention deficit hyperactivity disorder (ADHD).
📅 Journal publication: Oct 2024(online Jan 10, 2025)·Last updated: Nov 18, 2026
Centanafadine shows promise as a long-term ADHD treatment.
Long-term safety and efficacy of centanafadine, a triple reuptake inhibitor, are evaluated for treating adult ADHD. Centanafadine was generally well-tolerated with 61.4% experiencing treatment-emergent adverse events. Mean reduction in ADHD symptoms was significant at 52 weeks. As an open-label, phase 3 trial, these exploratory results suggest centanafadine may be a viable long-term treatment for adults with ADHD, pending further studies. Centanafadine shows promise for long-term management of adult ADHD with favorable safety and efficacy.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.